Consolidated segment reporting by business segment
Download(XLS, 40 KB)| Fresenius Medical Care | Fresenius Kabi | Fresenius Helios | Fresenius Vamed | Corporate | Fresenius Group | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| € in millions | 20221 | 20212 | Growth | 20223 | 20214 | Growth | 20225 | 20215 | Growth | 20226 | 20215 | Growth | 20227 | 20218 | Growth | 2022 | 2021 | Growth |
| Revenue | 19,398 | 17,619 | 10% | 7,850 | 7,193 | 9% | 11,716 | 10,891 | 8% | 2,359 | 2,297 | 3% | -483 | -480 | -1% | 40,840 | 37,520 | 9% |
| thereof contribution to consolidated revenue |
19,332 | 17,570 | 10% | 7,779 | 7,126 | 9% | 11,690 | 10,862 | 8% | 2,039 | 1,960 | 4% | 0 | 2 | -100% | 40,840 | 37,520 | 9% |
| thereof intercompany revenue | 66 | 49 | 35% | 71 | 67 | 6% | 26 | 29 | -10% | 320 | 337 | -5% | -483 | -482 | 0% | – | – | |
| contribution to consolidated revenue | 47 % | 47 % | 19 % | 19 % | 29 % | 29 % | 5 % | 5 % | 0 % | 0 % | 100 % | 100 % | ||||||
| EBITDA | 3,518 | 3,501 | 0% | 1,576 | 1,601 | -2% | 1,690 | 1,600 | 6% | 118 | 191 | -38% | -608 | -68 | -- | 6,294 | 6,825 | -8% |
| Depreciation and amortization | 1,701 | 1,586 | 7% | 496 | 448 | 11% | 505 | 473 | 7% | 98 | 90 | 9% | 173 | 70 | 147% | 2,973 | 2,667 | 11% |
| EBIT | 1,817 | 1,915 | -5% | 1,080 | 1,153 | -6% | 1,185 | 1,127 | 5% | 20 | 101 | -80% | -781 | -138 | -- | 3,321 | 4,158 | -20% |
| Net interest | -292 | -280 | -4% | -59 | -58 | -2% | -182 | -184 | 1% | -13 | -10 | -30% | 39 | 26 | 50% | -507 | -506 | 0% |
| Income taxes | -390 | -367 | -7% | -185 | -259 | 29% | -220 | -199 | -11% | 0 | -20 | 100% | 98 | 12 | -- | -697 | -833 | 16% |
| Net income attributable to shareholders of Fresenius SE & Co, KGaA |
913 | 1,018 | -10% | 780 | 778 | 0% | 766 | 728 | 5% | 1 | 67 | -99% | -1,088 | -773 | -41% | 1,372 | 1,818 | -25% |
| Operating cash flow | 2,167 | 2,489 | -13% | 841 | 1,203 | -30% | 1,367 | 1,204 | 14% | -44 | 151 | -129% | -133 | 31 | -- | 4,198 | 5,078 | -17% |
| Cash flow before acquisitions and dividends | 1,480 | 1,660 | -11% | 323 | 659 | -51% | 813 | 637 | 28% | -25 | 72 | -135% | -170 | 33 | -- | 2,421 | 3,061 | -21% |
| Total assets | 35,754 | 34,367 | 4% | 16,745 | 14,698 | 14% | 21,337 | 20,891 | 2% | 2,887 | 2,795 | 3% | -308 | -789 | 61% | 76,415 | 71,962 | 6% |
| Debt | 13,213 | 13,320 | -1% | 4,195 | 4,159 | 1% | 7,811 | 8,059 | -3% | 885 | 721 | 23% | 1,659 | 896 | 85% | 27,763 | 27,155 | 2% |
| Other operating liabilities | 6,156 | 6,199 | -1% | 3,842 | 3,250 | 18% | 3,424 | 3,176 | 8% | 994 | 994 | 0% | 349 | 385 | -9% | 14,765 | 14,004 | 5% |
| Capital expenditure, gross | 724 | 854 | -15% | 509 | 532 | -4% | 560 | 568 | -1% | 79 | 80 | -1% | 14 | -2 | -- | 1,886 | 2,032 | -7% |
| Acquisitions, gross / investments | 746 | 628 | 19% | 734 | 1 | -- | 82 | 453 | -82% | 17 | 1 | -- | 0 | 2 | -100% | 1,579 | 1,085 | 46% |
| Research and development expenses | 222 | 221 | 0% | 629 | 595 | 6% | 3 | 3 | 0% | – | – | 13 | -14 | 193% | 867 | 805 | 8% | |
| Employees (per capita on balance sheet date) |
128,044 | 130,251 | -2% | 42,063 | 41,397 | 2% | 125,700 | 123,484 | 2% | 20,184 | 19,721 | 2% | 929 | 1,225 | -24% | 316,920 | 316,078 | 0% |
| Key figures | ||||||||||||||||||
| EBITDA margin | 18.1% | 19.9% | 20.1% | 22.3% | 14.4% | 14.7% | 5.0% | 8.3% | 16.7%9 | 18.3%4 | ||||||||
| EBIT margin | 9.4% | 10.9% | 13.8% | 16.0% | 10.1% | 10.3% | 0.8% | 4.4% | 9.8%9 | 11.3%4 | ||||||||
| Depreciation and amortization in % of revenue |
8.8% | 9.0% | 6.3% | 6.2% | 4.3% | 4.3% | 4.2% | 3.9% | 7.3% | 7.1% | ||||||||
| Operating cash flow in % of revenue | 11.2% | 14.1% | 10.7% | 16.7% | 11.7% | 11.1% | -1.9% | 6.6% | 10.3% | 13.5% | ||||||||
| ROOA | 5.3% | 6.2% | 7.9% | 9.4% | 6.0% | 5.9% | 0.8% | 4.3% | 5.7%10 | 6.5%11 | ||||||||
| 1 Before costs related to FME25 program, impacts related to the war in Ukraine, hyperinflation Turkey, remeasurement Humacyte investment and net gain related to InterWell Health | ||||||||||||||||||
| 2 Before costs related to FME25 program | ||||||||||||||||||
| 3 Before revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix and hyperinflation Turkey | ||||||||||||||||||
| 4 Before revaluations of biosimilars contingent purchase price liabilities and expenses associated with the Fresenius cost and efficiency program | ||||||||||||||||||
| 5 Before expenses associated with the Fresenius cost and efficiency program | ||||||||||||||||||
| 6 Before expenses associated with the Fresenius cost and efficiency program and impacts related to the war in Ukraine | ||||||||||||||||||
| 7 After revaluations of biosimilarsBiosimilarsA biosimilar is a drug that is “similar” to another biologic drug already approved. contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties, remeasurement Humacyte investment and net gain related to InterWell Health | ||||||||||||||||||
| 8 After revaluations of biosimilars contingent purchase price liabilities and expenses associated with the Fresenius cost and efficiency program | ||||||||||||||||||
| 9 Before revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties, remeasurement Humacyte investment and net gain related to InterWell Health | ||||||||||||||||||
| 10 The underlying pro forma EBIT does not include revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties, remeasurement Humacyte investment and net gain related to InterWell Health | ||||||||||||||||||
| 11 The underlying pro forma EBIT does not include revaluations of biosimilars contingent purchase price liabilities and expenses associated with the Fresenius cost and efficiency program. | ||||||||||||||||||
| The consolidated segment reporting by business segment is an integral part of the notes. | ||||||||||||||||||
Consolidated segment reporting by region
Download(XLS, 36 KB)| Europe | North America | Asia-Pacific | |||||||
|---|---|---|---|---|---|---|---|---|---|
| € in millions | 2022 | 2021 | Growth | 2022 | 2021 | Growth | 2022 | 2021 | Growth |
| Revenue | 17,877 | 16,885 | 6% | 16,106 | 14,354 | 12% | 4,141 | 3,949 | 5% |
| contribution to consolidated revenue | 44% | 45% | 40% | 38% | 10% | 11% | |||
| EBIT | 413 | 873 | -53% | 1,899 | 2,198 | -14% | 782 | 861 | -9% |
| Depreciation and amortization | 1,154 | 1,073 | 8% | 1,494 | 1,268 | 18% | 219 | 227 | -4% |
| Total assets | 34,003 | 32,346 | 5% | 34,470 | 31,787 | 8% | 5,395 | 5,451 | -1% |
| Capital expenditure, gross | 1,071 | 1,154 | -7% | 588 | 635 | -7% | 119 | 141 | -16% |
| Acquisitions, gross / investments | 590 | 401 | 47% | 901 | 652 | 38% | 23 | 13 | 77% |
| Employees (per capita on balance sheet date) | 181,017 | 180,122 | 0% | 77,614 | 76,740 | 1% | 26,833 | 27,145 | -1% |
Consolidated segment reporting by region
Download(XLS, 36 KB)| Latin America | Africa | Fresenius Group | |||||||
|---|---|---|---|---|---|---|---|---|---|
| € in millions | 2022 | 2021 | Growth | 2022 | 2021 | Growth | 2022 | 2021 | Growth |
| Revenue | 2,182 | 1,830 | 19% | 534 | 502 | 6% | 40,840 | 37,520 | 9% |
| contribution to consolidated revenue | 5% | 5% | 1% | 1% | 100% | 100% | |||
| EBIT | 178 | 176 | 1% | 49 | 50 | -2% | 3,321 | 4,158 | -20% |
| Depreciation and amortization | 94 | 88 | 7% | 12 | 11 | 9% | 2,973 | 2,667 | 11% |
| Total assets | 2,252 | 2,082 | 8% | 295 | 296 | 0% | 76,415 | 71,962 | 6% |
| Capital expenditure, gross | 97 | 86 | 13% | 11 | 16 | -31% | 1,886 | 2,032 | -7% |
| Acquisitions, gross / investments | 65 | 18 | -- | 0 | 1 | -100% | 1,579 | 1,085 | 46% |
| Employees (per capita on balance sheet date) | 29,529 | 30,192 | -2% | 1,927 | 1,879 | 3% | 316,920 | 316,078 | 0% |
| The consolidated segment reporting by region is an integral part of the notes. | |||||||||